Autotelic Bio Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 22

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 15

Autotelic Bio General Information

Description

Developer of anti-cancer drugs designed to treat cancer patients. The company focuses on developing anti-cancer drugs for selective targeting and the precise optimization of antisense oligonucleotides designed to potentially deliver greater efficacy, safety, and tolerability compared to RNA interference medicines, enabling healthcare professionals to improve the effectiveness and reduce the side effects of cancer therapies to provide treatment alternatives for cancer patients.

Contact Information

Formerly Known As
Autotelic Korea
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 302, Building 2, Corporate Research Center, 194-41 Osongsaengmyeong 1-ro, Osong-eup
  • Heungdeok-gu
  • Cheongju, Chungcheongbuk 28160
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Room 302, Building 2, Corporate Research Center, 194-41 Osongsaengmyeong 1-ro, Osong-eup
  • Heungdeok-gu
  • Cheongju, Chungcheongbuk 28160
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Autotelic Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Secondary Transaction - Private Completed Clinical Trials - Phase 3
6. Later Stage VC (Series B) 28-Mar-2022 Completed Clinical Trials - Phase 3
5. Later Stage VC 14-Dec-2020 Completed Clinical Trials - Phase 3
4. Later Stage VC (Series A) 01-Feb-2020 Completed Clinical Trials - Phase 3
3. Angel (individual) 01-Aug-2018 Completed Startup
2. Accelerator/Incubator 01-Jul-2018 Completed Startup
1. Seed Round 01-Sep-2017 Completed Startup
To view Autotelic Bio’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Autotelic Bio Patents

Autotelic Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026141971-A1 Pharmaceutical composition for treating fibrosis comprising sglt-2 inhibitor and angiotensin receptor blocker Pending 26-Dec-2024
WO-2025234704-A1 Pharmaceutical composition for preventing or treating cancer-related diseases comprising antisense oligonucleotide and anticancer agent as active ingredients Pending 07-May-2024
WO-2025063819-A1 Composition for treating fibrotic disease comprising thiazole derivative compound Inactive 21-Sep-2023
WO-2025063820-A1 Composition for treating pulmonary fibrosis comprising thiazole derivative compound Inactive 21-Sep-2023
WO-2025063816-A1 Composition for treating uterine fibrosis comprising thiazole derivative compound Inactive 21-Sep-2023
To view Autotelic Bio’s complete patent history, request access »

Autotelic Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Autotelic Bio Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds
Colopl Next Corporate Venture Capital Minority
DreamStone Private Equity PE/Buyout Minority
DTN Investment (VC) Venture Capital Minority
Industrial Bank of Korea PE/Buyout Minority
LSK Investment Venture Capital Minority
You’re viewing 5 of 15 investors. Get the full list »

Autotelic Bio FAQs

  • When was Autotelic Bio founded?

    Autotelic Bio was founded in 2015.

  • Where is Autotelic Bio headquartered?

    Autotelic Bio is headquartered in Cheongju, South Korea.

  • What is the size of Autotelic Bio?

    Autotelic Bio has 22 total employees.

  • What industry is Autotelic Bio in?

    Autotelic Bio’s primary industry is Drug Discovery.

  • Is Autotelic Bio a private or public company?

    Autotelic Bio is a Private company.

  • What is Autotelic Bio’s current revenue?

    The current revenue for Autotelic Bio is .

  • How much funding has Autotelic Bio raised over time?

    Autotelic Bio has raised $22.3M.

  • Who are Autotelic Bio’s investors?

    Colopl Next, DreamStone Private Equity, DTN Investment (VC), Industrial Bank of Korea, and LSK Investment are 5 of 15 investors who have invested in Autotelic Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process